Predictors of Pulmonary Hypertension in Patients With Hypersensitivity Pneumonitis

Hypersensitivity pneumonitis (HP) is a complex immune mediated disorders caused by repeated inhalation of and sensitization to wide range of antigens including organic particles and chemical compounds, leading to exaggerated immuneresponse. Hypersenstivity pneumonitis is a common form of diffuse parenchymal lung diseases in Egypt .Pulmonary hypertension has been found as a complication of a number of diseases affecting the lung interstitium, including hypersensitivity pneumonitis, with subsequent affection of the life expectancy Rationale of the study: to find predictors for the development of pulmonary hypertension in patients with hypersensitivity pneumonitis

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pulmonary Hypertension Alveolitis, Extrinsic Allergic Cardiovascular Diseases Hypersensitivity Hypersensitivity Pneumonitis Hypersensitivity, Immediate Hypertension Hypertension, Pulmonary Immune System Diseases Lung Diseases Lung Diseases, Interstitial Respiratory Hypersensitivity Respiratory Tract Diseases Vascular Diseases

Age range

29 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kasr alainy school of medicine

Cairo, 11562, Egypt

About this study

Cross sectional study included 60 patients with established diagnosis of HP , work up includes history of exposure, clinical examination, HRCT chest, ABGs,6MWD, desaturation degree , spirometry, echocardiography and right heart catheter in patients with high echo probability of PH.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients with confirmed diagnosis of Hypersensitivity pneumonitis

Exclusion criteria

Other interstitial lung diseases

Treatment and study plan

right heart catheter

Procedure

Right heart catheterization was performed for 4 cases with high probability of pulmonary hypertension using multi-lumen swan ganz catheter.

Primary outcomes

Percentage of pulmonary hypertension in patients with HP

Time frame: 6 months

primary oucome

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Important dates

Study start: 2019
Primary completion: 2020
Study completion: 2021
First posted: Jul 14, 2022
Registry last updated: Jul 14, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed